





Hormone-free multi-symptom menopause relief designed to bring women's bodies back into balance.\* Naturally.



# Whole-body, all-in-one menopause care.

ONE DAILY TABLET RELIEVES 12 MENOPAUSE SYMPTOMS\*\*\*


HOT FLASHES
NIGHT SWEATS
SLEEP DISTURBANCES
NEGATIVE MOOD
MENOPAUSAL ANXIETY
VAGINAL DRYNESS
SEXUAL FRUSTRATION
URINARY TRACT DISCOMFORT
PHYSICAL & EMOTIONAL EXHAUSTION
JOINT & MUSCULAR DISCOMFORT
IRRITABILITY
MENOPAUSAL HEADACHES

## Estrogen has both alpha and beta receptors that are found in many tissues of the body.<sup>2,3</sup>

- Activation of ER alpha receptors might be involved in some side effects, such as proliferating growth in certain tissues.<sup>2</sup>
- Some phytoestrogens like red clover and soy isoflavones activate both estrogen alpha and beta receptors.<sup>4</sup>
- ERr 731 is also a phytoestrogen BUT has shown to have preferential binding affinity to ER beta receptors.<sup>1</sup>
- ER beta receptor activation inhibits ER alpha activation and thereby the cell growth in certain tissues, suggesting a safer option of using ERr 731 for peri- and postmenopausal symptoms.<sup>5</sup>

## • Breast • Ovary/testis • Bone • Bone • Central nervous system • Cardiovascular system • Uterus

## TISSUES WITH EITHER ALPHA OR BETA ERG • Liver • Vessels • White adipose tissue • Urinary tract • Intesinal lining




### How effective is Estrovera?

CLINICALLY PROVEN TO PROVIDE SUSTAINED RELIEF FOR OVER 2 YEARS WITH NO CHANGE IN SAFETY PARAMETERS.

- 12-week randomized, controlled trial followed by 96-week observational study of 109 perimenopausal women with hot flashes.<sup>1</sup>
- ERr 731® arm showed a dramatic and statistically significant improvement in MRS total scores compared to placebo.¹\*





#### Real women. Real results.



These patient satisfaction survey results were the focus of the 2023 Menopause Society's annual conference poster session. Scan QR code for more details.

IN A 2023 SURVEY, WOMEN NOTICED IMPROVEMENTS WITH THE FOLLOWING SYMPTOMS AFTER STARTING ESTROVERA†



HOT FLASHES



MOOD

SLEEP DISTURBANCES

### SIEED %

## Maximum bioavailability for rapid relief.

MORE THAN HALF OF PATIENTS EXPERIENCED RELIEF FROM HOT FLASHES AND NIGHT SWEATS WITHIN 4 WEEKS, AND AN ADDITIONAL 83% SAW RELIEF WITHIN 12 WEEKS.‡



WITHIN 4 WEEKS



WITHIN 12 WEEKS

#### ERr 731 vs Swedish pollen<sup>1,6</sup>

COMPARING THE 3-MONTH EFFECTIVENESS FOR THE MOST COMMON MENOPAUSE SYMPTOMS.

SYMPTOMS REDUCTION OF ERr 731 <sup>1</sup>	SYMPTOMS REDUCTION OF Swedish Pollen <sup>6</sup>
66%**	22%
74%**	No change
45%**	No change
69%**	No change
76%**	18.9%
ER beta agonist	Obscure
2-year study	3 months
	ERr 731 <sup>1</sup> 66%** 74%** 45%** 69%** 76%** ER beta agonist

#### Menopause support that's safe, convenient, and accessible.



#### 01. A proven safety profile

- A postmarketing surveillance study<sup>7</sup> demonstrated a low incidence of adverse events with ERr 731 (the main ingredient in Estrovera tablets) since its US introduction in 2009. This data supports the safety profile of ERr 731 when used as intended.\*
- In multicenter clinical studies<sup>8</sup> with ERr 731, safety is supported with no changes in gynecological findings including endometrial hyperplasia or abnormalities in breast tissues.\*

#### 02. All-in-one solution

- One tablet addresses 12 common menopause symptoms\*
- Once-daily dosing
- No progesterone or blood work required

#### 03. Care that's cost-effective

- Affordable cost per dose. Women who subscribe can save up to 10% and receive free shipping.\*\*\*
- · Metagenics offers a money-back guarantee if your patients aren't completely satisfied with their results.\*\*\*\*

For more information visit Metagenics.com/Estrovera or call: 800.692.9400



#### REFERENCES

- 1. Hasper I et al. Menopause. 2009;16:117-131.
- Papke A et al. J Steroid Biochem Mol Biol. 2009;117:176–184.
- 3. Wober Jet al. J Steroid Biochem Mol Biol. 2007;107:191–201.7.
- 4. Desmawati D et al. Open Access Maced J Med Sci. 2019;7(3):495–499.
- 5. Wilson M et al. Int. J. Mol. Sci. 2021;22:1032.
- Winther K et al. Climacteric. 2005;8(2):162-170.
- Chang J et al. Integr Med (Encinitas). 2016;15(3):34–39.
- Heger M et al. Menopause. 2006;13(5):744-759.
  - <sup>†</sup> Survey conducted online by Metagenics® March 2023 with 424 women currently or previously taking Estrovera.®
- <sup>††</sup>Compared with perimenopausal women receiving placebo, those receiving ERr 731° (the extract found in Estrovera®) experienced decreases in symptoms as indicated by the mean reduction in individual Menopause Rating Scale scores
- \*Survey conducted online by Metagenics® September 21 to October 5, 2020, with 75 women currently taking Estrovera.
- \*\*\* Additional terms and conditions apply.
- \*\*\*\* Money-back guarantee up to 60 days

#### **Supplement Facts**

Serving Size 1 Tablet Servings per Container 30

#### Amount Per Serving

Rhapontic Rhubarb

(Rheum rhaponticum L.) Root<sup>†</sup> Extract (ERr 731<sup>®</sup>) [Providing 2.2 mg rhaponticin and 1 mg desoxy-rhaponticin]

\*Daily Value not established.

Other Ingredients: Microcrystalline cellulose, stearic acid (vegetable), croscarmellose sodium, silica, and enteric coating (ethyl cellulose, hydroxypropylmethylcellulose, medium-chain triglycerides, ammonium hydroxide, sodium alginate, hydroxypropylcellulose, oleic acid, and stearic acid).



Non-GMO



Vegetarian



Gluten-free

Certified



These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease